CRMD

CorMedix Inc. (CRMD) is a New Jersey-based biopharmaceutical company focused on developing and commercializing therapeutic products to prevent and treat infectious and inflammatory diseases. Its lead product, DefenCath, is an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in patients with kidney disease undergoing dialysis. CRMD aims to address critical healthcare needs with innovative, non-antibiotic solutions.

As of February 21, 2025, CRMD’s stock has shown notable movement. After surging 133% from its late 2023 low post-earnings, it traded sideways for over a year. Recently, it formed a 6-day flag pattern, suggesting a potential breakout, though volatility remains tied to its pre-profitability stage and FDA approval milestones for DefenCath.